Recent Updates
Recently added Catalysts

M-M-RII manufactured with recombinant Human Albumin and VARIVAX

Phase 3

Measles | Monoclonal antibody | Infectious Disease |Merck & Company, Inc.|Last Updated: Oct 18, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment752

FDA Designations

No designations recorded

Clinical trial landscape

M-M-RII manufactured with recombinant Human Albumin and VARIVAX · 1 trial · 3 indications

Phase 3 1
NCT00432523Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)Measles
COMPLETED752 Analytics
PHASE3COMPLETED
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
Measles
NCT00432523752
Unlock trial analytics

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL

Interventions

NameTypeDescription
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®BIOLOGICAL -
Unlock Study Design Details

Eligibility Criteria

Age Range12 Months to 18 Months
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: 1. Healthy subject of either gender, 2. Age 12 to 18 months , 3. Consent form signed by both parent(s) or by the legal representative properly informed about the study, 4. Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card...

Countries:FranceGermany
Unlock Eligibility Criteria